Pekin Hardy Strauss’s Starling Oncology STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$114K Sell
18,000
-14,000
-44% -$83.7K 0.01% 465
2026
Q2
$174K Hold
32,000
– – 0.02% 481
2026
Q1
$98.2K Buy
32,000
+22,000
+220% +$67.5K 0.01% 459
2025
Q4
$35.6K Buy
+10,000
New +$37.1K ﹤0.01% 450

Other funds holding STLN

Pekin Hardy Strauss's STLN Position: Q3 2026 in Review

Pekin Hardy Strauss reduced its Starling Oncology (STLN) stake by 44% in Q3 2026, selling an estimated $83.7K and leaving 18,000 shares worth $114K. The position accounts for 0.01% of the portfolio, ranked #465.

Pekin Hardy Strauss first reported a position in STLN in Q4 2025 and has held it in 4 quarters since. The position peaked at $174K in Q2 2026. 131 funds tracked by Wall St. Rank hold STLN as of Q3 2026.

  • Pekin Hardy Strauss held 18,000 shares of Starling Oncology worth $114K as of Q3 2026.
  • Pekin Hardy Strauss sold 14,000 Starling Oncology shares in Q3 2026, an estimated $83.7K.
  • Starling Oncology made up 0.01% of Pekin Hardy Strauss's portfolio in Q3 2026, its #465 holding.
  • Pekin Hardy Strauss first reported a position in Starling Oncology in Q4 2025 and has held it in 4 quarters since.
  • Pekin Hardy Strauss's Starling Oncology position peaked at $174K in Q2 2026.
  • 131 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.

Based on Pekin Hardy Strauss's 13F filing for Q3 2026, filed 2 Nov 2026.